Belite Bio (BLTE)
(Delayed Data from NSDQ)
$50.99 USD
+0.09 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $50.91 -0.08 (-0.16%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Belite Bio, Inc Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 13 | 10 | 6 | 0 |
Income After Depreciation & Amortization | -32 | -13 | -10 | -6 | 0 |
Non-Operating Income | 0 | 0 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -32 | -13 | -10 | -6 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -32 | -13 | -10 | -6 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -32 | -13 | -10 | -6 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -13 | -10 | -6 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -32 | -13 | -10 | -6 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.59 | 8.79 | 9.57 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.19 | -0.65 | -1.01 | NA | NA |
Diluted Net EPS (GAAP) | -1.19 | -0.63 | -1.01 | NA | NA |
Fiscal Year end for Belite Bio, Inc Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.47 | 8.33 | 6.95 | 10.96 | 6.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.47 | -8.33 | -6.95 | -10.96 | -6.88 |
Non-Operating Income | 0.98 | 0.46 | -0.09 | 0.03 | 0.06 |
Interest Expense | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
Pretax Income | -9.49 | -7.87 | -6.99 | -10.93 | -6.81 |
Income Taxes | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.49 | -7.87 | -6.99 | -10.94 | -6.81 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.49 | -7.87 | -6.99 | -10.94 | -6.81 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 30.32 | 29.68 | 28.32 | 27.32 | 25.79 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.27 | -0.25 | -0.40 | -0.26 |
Diluted Net EPS (GAAP) | -0.31 | -0.27 | -0.20 | -0.40 | -0.26 |